Susceptibility Test Methods: Fastidious Bacteria*

Romney M. Humphries; Janet A. Hindler

doi:10.1128/9781555817381.ch74

Chapter 74 : Susceptibility Test Methods: Fastidious Bacteria*

Authors: Romney M. Humphries, Janet A. Hindler

Content Type: Reference

Publication Year: 2015

Category: Clinical Microbiology

Book DOI: 10.1128/9781555817381

Chapter DOI: 10.1128/9781555817381.ch74

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:

Susceptibility Test Methods: Fastidious Bacteria*, Page 1 of 2

< Previous page | Next page > /docserver/preview/fulltext/10.1128/9781555817381/9781555817381.ch74-1.gif /docserver/preview/fulltext/10.1128/9781555817381/9781555817381.ch74-2.gif

Abstract:

This chapter summarizes key considerations for antimicrobial susceptibility testing of fastidious and infrequently isolated bacteria. Up-to-date data on the global incidence of resistance, as documented by international, national, and local surveillance studies for these organisms, are presented. Important resistance mechanisms are discussed for many organisms, including Streptococcus spp., Haemophilus influenzae, Neisseria gonorrhoeae, and Neisseria meningitidis. This chapter also describes standard methods for testing the infrequently isolated or fastidious bacteria included in the CLSI M100 standard and M45 guideline.

Citation: Humphries R, Hindler J. 2015. Susceptibility Test Methods: Fastidious Bacteria*, p 1314-1341. In Jorgensen J, Pfaller M, Carroll K, Funke G, Landry M, Richter S, Warnock D (ed), Manual of Clinical Microbiology, Eleventh Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817381.ch74

Highlighted Text: Show | Hide

Full text loading...

References

/content/book/10.1128/9781555817381.mcm11.ch74

1. Clinical and Laboratory Standards Institute. 2013. Performance Standards for Antimicrobial Susceptibility Testing. Twenty-Third Informational Supplement. M100-S23. CLSI, Wayne, PA.

2. Clinical and Laboratory Standards Institute. 2010. Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria, 2nd ed. Approved Guideline M45-A2. CLSI, Wayne, PA.

3. Hakenbeck R,, Bruckner R,, Denapaite D,, Maurer P. 2012. Molecular mechanisms of beta-lactam resistance in Streptococcus pneumoniae. Future Microbiol 7: 395– 410.

4. Reinert RR. 2009. The antimicrobial resistance profile of Streptococcus pneumoniae. Clin Microbiol Infect 15( Suppl 3) : 7– 11.

5. Dagan R. 2009. Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae. Clin Microbiol Infect 15( Suppl 3) : 16– 20.

6. Kyaw MH,, Lynfield R,, Schaffner W,, Craig AS,, Hadler J,, Reingold A,, Thomas AR,, Harrison LH,, Bennett NM,, Farley MM,, Facklam RR,, Jorgensen JH,, Besser J,, Zell ER,, Schuchat A,, Whitney CG. 2006. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 354: 1455– 1463.

7. Link-Gelles R,, Thomas A,, Lynfield R,, Petit S,, Schaffner W,, Harrison L,, Farley MM,, Aragon D,, Nicols M,, Kirley PD,, Zansky S,, Jorgensen J,, Juni BA,, Jackson D,, Moore M,, Lipsitch M. 2013. Geographic and temporal trends in antimicrobial nonsusceptibility in Streptococcus pneumoniae in the post-vaccine era in the United States. J Infect Dis 208: 1266– 1273.

8. Jones RN,, Sader HS,, Mendes RE,, Flamm RK. 2013. Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998–2011). Diagn Microbiol Infect Dis 75: 107– 109.

9. Hampton LM,, Farley MM,, Schaffner W,, Thomas A,, Reingold A,, Harrison LH,, Lynfield R,, Bennett NM,, Petit S,, Gershman K,, Baumbach J,, Beall B,, Jorgensen J,, Glennen A,, Zell ER,, Moore M. 2012. Prevention of antibiotic-nonsusceptible Streptococcus pneumoniae with conjugate vaccines. J Infect Dis 205: 401– 411.

10. Wroe PC,, Lee GM,, Finkelstein JA,, Pelton SI,, Hanage WP,, Lipsitch M,, Stevenson AE,, Rifas-Shiman SL,, Kleinman K,, Dutta-Linn MM,, Hinrichsen VL,, Lakoma M,, Huang SS. 2012. Pneumococcal carriage and antibiotic resistance in young children before 13-valent conjugate vaccine. Pediatr Infect Dis J 31: 249– 254.

11. Hulten KG,, Kaplan SL,, Lamberth LB,, Barson WJ,, Romero JR,, Lin PL,, Bradley JS,, Givner LB,, Tan TQ,, Hoffman JA,, Mason EO. 2013. Changes in Streptococcus pneumoniae serotype 19A invasive infections in children from 1993 to 2011. J Clin Microbiol 51: 1294– 1297.

12. Weinstein MP,, Klugman KP,, Jones RN. 2009. Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance. Clin Infect Dis 48: 1596– 1600.

13. Brandon M,, Dowzicky MJ. 2013. Antimicrobial susceptibility among gram-positive organisms collected from pediatric patients globally between 2004 and 2011: results from the tigecycline evaluation and surveillance trial. J Clin Microbiol 51: 2371– 2378.

14. Tsai HY,, Chen YH,, Liao CH,, Lu PL,, Huang CH,, Lu CT,, Chuang YC,, Tsao SM,, Chen YS,, Liu YC,, Chen WY,, Jang TN,, Lin HC,, Chen CM,, Shi ZY,, Pan SC,, Yang JL,, Kung HC,, Liu CE,, Cheng YJ,, Liu JW,, Sun W,, Wang LS,, Ko WC,, Yu KW,, Chiang PC,, Lee MH,, Lee CM,, Hsu GJ,, Hsueh PR. 2013. Trends in the antimicrobial susceptibilities and serotypes of Streptococcus pneumoniae: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2006–2010. Int J Antimicrob Agents 42: 312– 316.

15. Sader HS,, Flamm RK,, Jones RN. 2013. Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010). Diagn Microbiol Infect Dis 76: 61– 68.

16. Pottumarthy S,, Fritsche TR,, Jones RN. 2005. Comparative activity of oral and parenteral cephalosporins tested against multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1997–2003). Diagn Microbiol Infect Dis 51: 147– 150.

17. Inoue M,, Farrell DJ,, Kaneko K,, Akizawa K,, Fujita S,, Kaku M,, Igari J,, Yamaguchi K,, Yamanaka K,, Murase M,, Asari S,, Hirakata Y,, Baba H,, Itaha H. 2008. Antimicrobial susceptibility of respiratory tract pathogens in Japan during PROTEKT years 1–5 (1999–2004). Microb Drug Resist 14: 109– 117.

18. Lonks JR,, Garau J,, Gomez L,, Xercavins M,, Ochoa de Echaguen A,, Gareen IF,, Reiss PT,, Medeiros AA. 2002. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 35: 556– 564.

19. Jorgensen JH,, McElmeel ML,, Fulcher LC,, McGee L,, Glennen A. 2011. Evaluation of disk approximation and single-well broth tests for detection of inducible clindamycin resistance in Streptococcus pneumoniae. J Clin Microbiol 49: 3332– 3333.

20. Blasi F,, Farrell DJ,, Dubreuil L. 2009. Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with community-acquired respiratory tract infections: the Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin study year 5 (2003–2004). Diagn Microbiol Infect Dis 63: 302– 308.

21. Beekmann SE,, Heilmann KP,, Richter SS,, García-de-Lomas J,, Doern GV. 2005. Antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and group A beta-haemolytic streptococci in 2002–2003. Results of the multinational GRASP Surveillance Program. Int J Antimicrob Agents 25: 148– 156.

22. Patel SN,, McGeer A,, Melano R,, Tyrrell GJ,, Green K,, Pillai DR,, Low DE. 2011. Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Antimicrob Agents Chemother 55: 3703– 3708.

23. Adam HJ,, Baxter MR,, Davidson RJ,, Rubinstein E,, Fanella S,, Karlowsky JA,, Lagace-Wiens PR,, Hoban DJ,, Zhanel GG. 2013. Comparison of pathogens and their antimicrobial resistance patterns in paediatric, adult and elderly patients in Canadian hospitals. J Antimicrob Chemother 68( Suppl 1) : i31– i37.

24. Jones RN,, Kohno S,, Ono Y,, Ross JE,, Yanagihara K. 2009. ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countries. Diagn Microbiol Infect Dis 64: 191– 201.

25. Jones RN,, Stilwell MG,, Wilson ML,, Mendes RE. 2013. Contemporary tetracycline susceptibility testing: doxycycline MIC methods and interpretive criteria (CLSI and EUCAST) performance when testing Gram-positive pathogens. Diagn Microbiol Infect Dis 76: 69– 72.

26. Dallas SD,, McGee L,, Limbago B,, Patel JB,, McElmeel ML,, Fulcher LC,, Lonsway DR,, Jorgensen JH. 2013. Development of doxycycline MIC and disk diffusion interpretive breakpoints and revision of tetracycline breakpoints for Streptococcus pneumoniae. J Clin Microbiol 51: 1798– 1802.

27. Jorgensen JH,, Ferraro MJ,, McElmeel ML,, Spargo J,, Swenson JM,, Tenover FC. 1994. Detection of penicillin and extended-spectrum cephalosporin resistance among Streptococcus pneumoniae clinical isolates by use of the E test. J Clin Microbiol 32: 159– 163.

28. Mittman SA,, Huard RC,, Della-Latta P,, Whittier S. 2009. Comparison of BD Phoenix to Vitek 2, MicroScan MICroSTREP, and Etest for antimicrobial susceptibility testing of Streptococcus pneumoniae. J Clin Microbiol 47: 3557– 3561.

29. Jorgensen JH,, Barry AL,, Traczewski MM,, Sahm DF,, McElmeel ML,, Crawford SA. 2000. Rapid automated antimicrobial susceptibility testing of Streptococcus pneumoniae by use of the bioMerieux Vitek 2. J Clin Microbiol 38: 2814– 2818.

30. Richter SS,, Howard WJ,, Weinstein MP,, Bruckner DA,, Hindler JF,, Saubolle M,, Doern GV. 2007. Multicenter evaluation of the BD Phoenix Automated Microbiology System for antimicrobial susceptibility testing of Streptococcus species. J Clin Microbiol 45: 2863– 2871.

31. Betriu C,, Gomez M,, Sanchez A,, Cruceyra A,, Romero J,, Picazo JJ. 1994. Antibiotic resistance and penicillin tolerance in clinical isolates of group B streptococci. Antimicrob Agents Chemother 38: 2183– 2186.

32. Traub WH,, Leonhard B. 1997. Comparative susceptibility of clinical group A, B, C, F, and G β-hemolytic streptococcal isolates to 24 antimicrobial drugs. Chemotherapy 43: 10– 20.

33. Kimura K,, Suzuki S,, Wachino J,, Kurokawa H,, Yamane K,, Shibata N,, Nagano N,, Kato H,, Shibayama K,, Arakawa Y. 2008. First molecular characterization of group B streptococci with reduced penicillin susceptibility. Antimicrob Agents Chemother 52: 2890– 2897.

34. Kimura K,, Nagano N,, Nagano Y,, Suzuki S,, Wachino J,, Shibayama K,, Arakawa Y. 2013. High frequency of fluoroquinolone- and macrolide-resistant streptococci among clinically isolated group B streptococci with reduced penicillin susceptibility. J Antimicrob Chemother 68: 539– 542.

35. Dahesh S,, Hensler ME,, Van Sorge NM,, Gertz RE Jr,, Schrag S,, Nizet V,, Beall BW. 2008. Point mutation in the group B streptococcal pbp2x gene conferring decreased susceptibility to beta-lactam antibiotics. Antimicrob Agents Chemother 52: 2915– 2918.

36. Gaudreau C,, Lecours R,, Ismail J,, Gagnon S,, Jette L,, Roger M. 2010. Prosthetic hip joint infection with a Streptococcus agalactiae isolate not susceptible to penicillin G and ceftriaxone. J Antimicrob Chemother 65: 594– 595.

37. Longtin J,, Vermeiren C,, Shahinas D,, Tamber GS,, McGeer A,, Low DE,, Katz K,, Pillai DR. 2011. Novel mutations in a patient isolate of Streptococcus agalactiae with reduced penicillin susceptibility emerging after long-term oral suppressive therapy. Antimicrob Agents Chemother 55: 2983– 2985.

38. Paukner S,, Sader HS,, Ivezic-Schoenfeld Z,, Jones RN. 2013. Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY Antimicrobial Surveillance Program (2010). Antimicrob Agents Chemother 57: 4489– 4495.

39. Jones RN,, Sader HS,, Flamm RK. 2013. Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011). Diagn Microbiol Infect Dis 75: 304– 307.

40. Zhanel GG,, Adam HJ,, Baxter MR,, Fuller J,, Nichol KA,, Denisuik AJ,, Lagace-Wiens PR,, Walkty A,, Karlowsky JA,, Schweizer F,, Hoban DJ. 2013. Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007–11 study. J Antimicrob Chemother 68( Suppl 1) : i7– i22.

41. Gray KL,, Fulcher LC,, McElmeel ML,, Xenakis EM,, Jorgensen JH. 2011. The outpatient institutional antibiogram does not accurately reflect the susceptibility of prepartum group B streptococcal isolates to erythromycin and clindamycin. Diagn Microbiol Infect Dis 71: 457– 459.

42. Sader HS,, Flamm RK,, Jones RN. 2013. Antimicrobial activity of daptomycin tested against Gram-positive pathogens collected in Europe, Latin America, and selected countries in the Asia-Pacific Region (2011). Diagn Microbiol Infect Dis 75: 417– 422.

43. Yap R,, Mermel L,, Maglio J. 2006. Antimicrobial resistance of community-acquired bloodstream isolates of viridans group streptococci. Infection 34: 339– 341.

44. Moet GJ,, Dowzicky MJ,, Jones RN. 2007. Tigecycline (GAR-936) activity against Streptococcus gallolyticus ( bovis) and viridans group streptococci. Diagn Microbiol Infect Dis 57: 333– 336.

45. Jones RN,, Ross JE,, Castanheira M,, Mendes RE. 2008. United States resistance surveillance results for linezolid (LEADER Program for 2007). Diagn Microbiol Infect Dis 62: 416– 426.

46. Poyart C,, Pierre C,, Quesne G,, Pron B,, Berche P,, Trieu-Cuot P. 1997. Emergence of vancomycin resistance in the genus Streptococcus: characterization of a VAN-B transferable determinant in Streptococcus bovis. Antimicrob Agents Chemother 41: 24– 29.

47. Krcmery V Jr,, Spanik S,, Trupl J. 1996. First report of vancomycin-resistant Streptococcus mitis bacteremia in a leukemic patient after prophylaxis with quinolones and during treatment with vancomycin. J Chemother 8: 325– 326.

48. Jones RN,, Stilwell MG,, Hogan PA,, Sheehan DJ. 2007. Activity of linezolid against 3,251 strains of uncommonly isolated gram-positive organisms: report from the SENTRY antimicrobial surveillance program. Antimicrob Agents Chemother 51: 1491– 1493.

49. Sader HS,, Streit JM,, Fritsche TR,, Jones RN. 2006. Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme. Clin Microbiol Infect 12: 844– 852.

50. Palacio F,, Lewis JS,, Sadkowski L,, Echevarria K,, Jorgensen JH. 2011. Breakthrough bacteremia and septic shock due to Streptococcus anginosus resistant to daptomycin in a patient receiving daptomycin therapy. Antimicrob Agents Chemother 55: 3639– 3640.

51. Baddour LM,, Wilson WR,, Bayer AS,, Fowler VG Jr,, Bolger AF,, Levison ME,, Ferrieri P,, Gerber MA,, Tani LY,, Gewitz MH,, Tong DC,, Steckelberg JM,, Baltimore RS,, Shulman ST,, Burns JC,, Falace DA,, Newburger JW,, Pallasch TJ,, Takahashi M,, Taubert KA. 2005. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 111: e394– e434.

52. Jorgensen JH,, McElmeel ML,, Fulcher LC,, McGee L,, Richter SS,, Heilmann KP,, Ferraro MJ,, Spargo J,, Glennen A. 2011. Collaborative evaluation of an erythromycin-clindamycin combination well for detection of inducible clindamycin resistance in beta-hemolytic streptococci by use of the CLSI broth microdilution method. J Clin Microbiol 49: 2884– 2886.

53. Kim SJ,, Uh Y,, Jang IH,, Lee KS,, Park SD,, Yoon KJ. 2011. Evaluation of the MicroScan MICroSTREP plus antimicrobial panel for testing beta-hemolytic streptococci and viridans group streptococci. Korean J Lab Med 31: 185– 190.

54. Kimura K,, Nagano N,, Nagano Y,, Wachino J,, Shibayama K,, Arakawa Y. 2013. Ability of the VITEK(R) 2 system to detect group B streptococci with reduced penicillin susceptibility (PRGBS). J Antimicrob Chemother 68: 1442– 1444.

55. Jones R,, Johnson D,, Erwin M,, Beach M,, Biedenbach D,, Pfaller M. 1999. Comparative antimicrobial activity of gatifloxacin tested against Streptococcus spp. including quality control guidelines and Etest method validation. Diagn Microbiol Infect Dis 34: 91– 98.

56. Rosser SJ,, Alfa MJ,, Hoban S,, Kennedy J,, Harding GK. 1999. E Test versus agar dilution for antimicrobial susceptibility testing of viridans group streptococci. J Clin Microbiol 37: 26– 30.

57. Farrell DJ,, Morrissey I,, Bakker S,, Buckridge S,, Felmingham D. 2005. Global distribution of TEM-1 and ROB-1 beta-lactamases in Haemophilus influenzae. J Antimicrob Chemother 56: 773– 776.

58. Tristram SG,, Littlejohn R,, Bradbury RS. 2010. blaROB-1 presence on pB1000 in Haemophilus influenzae is widespread, and variable cefaclor resistance is associated with altered penicillin-binding proteins. Antimicrob Agents Chemother 54: 4945– 4947.

59. Trepod CM,, Mott JE. 2005. Elucidation of essential and nonessential genes in the Haemophilus influenzae Rd cell wall biosynthetic pathway by targeted gene disruption. Antimicrob Agents Chemother 49: 824– 826.

60. Tristram S,, Jacobs MR,, Appelbaum PC. 2007. Antimicrobial resistance in Haemophilus influenzae. Clin Microbiol Rev 20: 368– 389.

61. Barbosa AR,, Giufre M,, Cerquetti M,, Bajanca-Lavado MP. 2011. Polymorphism in ftsI gene and β-lactam susceptibility in Portuguese Haemophilus influenzae strains: clonal dissemination of beta-lactamase-positive isolates with decreased susceptibility to amoxicillin/clavulanic acid. J Antimicrob Chemother 66: 788– 796.

62. Norskov-Lauritsen N,, Ridderberg W,, Erikstrup LT,, Fuursted K. 2011. Evaluation of disk diffusion methods to detect low-level beta-lactamase-negative ampicillin-resistant Haemophilus influenzae. APMIS 119: 385– 392.

63. Witherden EA,, Montgomery J,, Henderson B,, Tristram SG. 2011. Prevalence and genotypic characteristics of β-lactamase-negative ampicillin-resistant Haemophilus influenzae in Australia. J Antimicrob Chemother 66: 1013– 1015.

64. Dabernat H,, Delmas C. 2012. Epidemiology and evolution of antibiotic resistance of Haemophilus influenzae in children 5 years of age or less in France, 2001–2008: a retrospective database analysis. Eur J Clin Microbiol Infect Dis 31: 2745– 2753.

65. Watanabe A,, Yanagihara K,, Matsumoto T,, Kohno S,, Aoki N,, Oguri T,, Sato J,, Muratani T,, Yagisawa M,, Ogasawara K,, Koashi N,, Kozuki T,, Komoto A,, Takahashi Y,, Tsuji T,, Terada M,, Nakanishi K,, Hattori R,, Hirako Y,, Maruo A,, Minamitani S,, Morita K,, Wakamura T,, Sunakawa K,, Hanaki H,, Ohsaki Y,, Honda Y,, Sasaoka S,, Takeda H,, Ikeda H,, Sugai A,, Miki M,, Nakanowatari S,, Takahashi H,, Utagawa M,, Kobayashi N,, Takasaki J,, Konosaki H,, Aoki Y,, Shoji M,, Goto H,, Saraya T,, Kurai D,, Okazaki M,, Kobayashi Y,, Katono Y,, Kawana A,, Saionji K,, Miyazawa N,, Sato Y,, Watanuki Y,, Kudo M,, Ehara S,, Tsukada H,, Imai Y,, Watabe N,, Aso S,, Honma Y,, Mikamo H,, Yamagishi Y,, Takesue Y,, Wada Y,, Nakamura T,, Mitsuno N,, Mikasa K,, Kasahara K,, Uno K,, Sano R,, Miyashita N,, Kurokawa Y,, Takaya M,, Kuwabara M,, Watanabe Y,, Doi M,, Shimizu S,, Negayama K,, Kadota J,, Hiramatsu K,, Morinaga Y,, Honda J,, Fujita M,, Iwata S,, Iwamoto A,, Ezaki T,, Onodera S,, Kusachi S,, Tateda K,, Tanaka M,, Totsuka K,, Niki Y. 2012. Nationwide surveillance of bacterial respiratory pathogens conducted by the Surveillance Committee of Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Clinical Microbiology in 2009: general view of the pathogens’ antibacterial susceptibility. J Infect Chemother 18: 609– 620.

66. Yang Q,, Xu Y,, Chen M,, Wang H,, Sun H,, Hu Y,, Zhang R,, Duan Q,, Zhuo C,, Cao B,, Liu Y,, Yu Y,, Sun Z,, Chu Y. 2012. In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China. Diagn Microbiol Infect Dis 73: 187– 191.

67. Pfaller MA,, Farrell DJ,, Sader HS,, Jones RN. 2012. AWARE Ceftaroline Surveillance Program (2008–2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States. Clin Infect Dis 55( Suppl 3) : S187– S193.

68. Wang H,, Chen M,, Xu Y,, Sun H,, Yang Q,, Hu Y,, Cao B,, Chu Y,, Liu Y,, Zhang R,, Yu Y,, Sun Z,, Zhuo C,, Ni Y,, Hu B,, Tan TY,, Hsueh PR,, Wang JH,, Ko WC,, Chen YH,, Wahjono H. 2011. Antimicrobial susceptibility of bacterial pathogens associated with community-acquired respiratory tract infections in Asia: report from the Community-Acquired Respiratory Tract Infection Pathogen Surveillance (CARTIPS) study, 2009–2010. Int J Antimicrob Agents 38: 376– 383.

69. Lulitanond A,, Chanawong A,, Pienthaweechai K,, Sribenjalux P,, Tavichakorntrakool R,, Wilailuckana C,, Puang-Ngern P,, Saetung P. 2012. Prevalence of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae isolated from patients of a teaching hospital in Thailand. Jpn J Infect Dis 65: 122– 125.

70. Resman F,, Ristovski M,, Forsgren A,, Kaijser B,, Kronvall G,, Medstrand P,, Melander E,, Odenholt I,, Riesbeck K. 2012. Increase of beta-lactam-resistant invasive Haemophilus influenzae in Sweden, 1997 to 2010. Antimicrob Agents Chemother 56: 4408– 4415.

71. Jansen WT,, Verel A,, Beitsma M,, Verhoef J,, Milatovic D. 2008. Surveillance study of the susceptibility of Haemophilus influenzae to various antibacterial agents in Europe and Canada. Curr Med Res Opin 24: 2853– 2861.

72. Farrell DJ,, Flamm RK,, Jones RN,, Sader HS. 2013. Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010). Diagn Microbiol Infect Dis 75: 86– 88.

73. Chang CM,, Lauderdale TL,, Lee HC,, Lee NY,, Wu CJ,, Chen PL,, Lee CC,, Chen PC,, Ko WC. 2010. Colonisation of fluoroquinolone-resistant Haemophilus influenzae among nursing home residents in southern Taiwan. J Hosp Infect 75: 304– 308.

74. Garcia-Cobos S,, Arroyo M,, Perez-Vazquez M,, Aracil B,, Oteo J,, Campos J. 2013. Evaluation of the EUCAST disc diffusion susceptibility testing method for Haemophilus influenzae based on the resistance mechanism to beta-lactam antibiotics. J Antimicrob Chemother 68: 159– 163.

75. Sjolund-Karlsson M,, Reimer A,, Folster JP,, Walker M,, Dahourou GA,, Batra DG,, Martin I,, Joyce K,, Parsons MB,, Boncy J,, Whichard JM,, Gilmour MW. 2011. Drug-resistance mechanisms in Vibrio cholerae O1 outbreak strain, Haiti, 2010. Emerg Infect Dis 17: 2151– 2154.

76. Billal DS,, Hotomi M,, Yamanaka N. 2007. Can the Etest correctly determine the MICs of beta-lactam and cephalosporin antibiotics for beta-lactamase-negative ampicillin-resistant Haemophilus influenzae? Antimicrob Agents Chemother 51: 3463– 3464.

77. Centers for Disease Control and Prevention. 2012. Update to CDC’s sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep 61: 590– 594.

78. Ohnishi M,, Ono E,, Shimuta K,, Watanabe H,, Okamura N. 2010. Identification of TEM-135 beta-lactamase in penicillinase-producing Neisseria gonorrhoeae strains in Japan. Antimicrob Agents Chemother 54: 3021– 3023.

79. Osaka K,, Takakura T,, Narukawa K,, Takahata M,, Endo K,, Kiyota H,, Onodera S. 2008. Analysis of amino acid sequences of penicillin-binding protein 2 in clinical isolates of Neisseria gonorrhoeae with reduced susceptibility to cefixime and ceftriaxone. J Infect Chemother 14: 195– 203.

80. Ison CA,, Town K,, Obi C,, Chisholm S,, Hughes G,, Livermore DM,, Lowndes CM. 2013. Decreased susceptibility to cephalosporins among gonococci: data from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) in England and Wales, 2007–2011. Lancet Infect Dis 13: 762– 768.

81. Allen VG,, Mitterni L,, Seah C,, Rebbapragada A,, Martin IE,, Lee C,, Siebert H,, Towns L,, Melano RG,, Low DE. 2013. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA 309: 163– 170.

82. Pandori M,, Barry PM,, Wu A,, Ren A,, Whittington WL,, Liska S,, Klausner JD. 2009. Mosaic penicillin-binding protein 2 in Neisseria gonorrhoeae isolates collected in 2008 in San Francisco, California. Antimicrob Agents Chemother 53: 4032– 4034.

83. Lindberg R,, Fredlund H,, Nicholas R,, Unemo M. 2007. Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA. Antimicrob Agents Chemother 51: 2117– 2122.

84. Unemo M,, Golparian D,, Syversen G,, Vestrheim DF,, Moi H. 2010. Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010. Euro Surveill 15( 47): pii=19721.

85. Kirkcaldy RD,, Zaidi A,, Hook EW III,, Holmes KH,, Soge O,, del Rio C,, Hall G,, Papp J,, Bolan G,, Weinstock HS. 2013. Neisseria gonorrhoeae antimicrobial resistance among men who have sex with men and men who have sex exclusively with women: the Gonococcal Isolate Surveillance Project, 2005–2010. Ann Intern Med 158: 321– 328.

86. Lahra MM. 2012. Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific and South East Asian Regions, 2010. Commun Dis Intell Q Rep 36: 95– 100.

87. Ohnishi M,, Saika T,, Hoshina S,, Iwasaku K,, Nakayama S,, Watanabe H,, Kitawaki J. 2011. Ceftriaxone-resistant Neisseria gonorrhoeae, Japan. Emerg Infect Dis 17: 148– 149.

88. Unemo M,, Golparian D,, Nicholas R,, Ohnishi M,, Gallay A,, Sednaoui P. 2012. High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother 56: 1273– 1280.

89. Camara J,, Serra J,, Ayats J,, Bastida T,, Carnicer-Pont D,, Andreu A,, Ardanuy C. 2012. Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. J Antimicrob Chemother 67: 1858– 1860.

90. Ohnishi M,, Golparian D,, Shimuta K,, Saika T,, Hoshina S,, Iwasaku K,, Nakayama S,, Kitawaki J,, Unemo M. 2011. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother 55: 3538– 3545.

91. Unemo M,, Golparian D,, Limnios A,, Whiley D,, Ohnishi M,, Lahra MM,, Tapsall JW. 2012. In vitro activity of ertapenem versus ceftriaxone against Neisseria gonorrhoeae isolates with highly diverse ceftriaxone MIC values and effects of ceftriaxone resistance determinants: ertapenem for treatment of gonorrhea? Antimicrob Agents Chemother 56: 3603– 3609.

92. Clinical and Laboratory Standards Institute. 2012. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, 9th ed. Approved standard M07-A9. CLSI, Wayne, PA.

93. Clinical and Laboratory Standards Institute. 2012. Performance Standards for Antimicrobial Disk Susceptibility Tests, 11th ed. Approved standard M02-A11. CLSI, Wayne, PA.

94. Liao CH,, Lai CC,, Hsu MS,, Chu FY,, Wu MY,, Huang YT,, Hsueh PR. 2010. Antimicrobial susceptibility of Neisseria gonorrhoeae isolates determined by the agar dilution, disk diffusion and Etest methods: comparison of results using GC agar and chocolate agar. Int J Antimicrob Agents 35: 457– 460.

95. Limnios A,, Tapsall J,, Kahlmeter J,, Hogan T,, Ray S,, Lam A,, Unemo M. 2011. Cefpodoxime 10 μg disc screening test for detection of Neisseria gonorrhoeae with mosaic PBP2 and decreased susceptibility to extended-spectrum cephalosporins for public health purposes. APMIS 119: 356– 363.

96. Singh V,, Bala M,, Kakran M,, Ramesh V. 2012. Comparative assessment of CDS, CLSI disc diffusion and Etest techniques for antimicrobial susceptibility testing of Neisseria gonorrhoeae: a 6-year study. BMJ Open 2: e000969.

97. Goire N,, Ohnishi M,, Limnios AE,, Lahra MM,, Lambert SB,, Nimmo GR,, Nissen MD,, Sloots TP,, Whiley DM. 2012. Enhanced gonococcal antimicrobial surveillance in the era of ceftriaxone resistance: a real-time PCR assay for direct detection of the Neisseria gonorrhoeae H041 strain. J Antimicrob Chemother 67: 902– 905.

98. Balashov S,, Mordechai E,, Adelson ME,, Gygax SE. 2013. Multiplex bead suspension array for screening Neisseria gonorrhoeae antibiotic resistance genetic determinants in noncultured clinical samples. J Mol Diagn 15: 116– 129.

99. Bolan GA,, Sparling PF,, Wasserheit JN. 2012. The emerging threat of untreatable gonococcal infection. N Engl J Med 366: 485– 487.

100. Ibarz-Pavon AB,, Lemos AP,, Gorla MC,, Regueira M,, Gabastou JM. 2012. Laboratory-based surveillance of Neisseria meningitidis isolates from disease cases in Latin American and Caribbean countries, SIREVA II 2006–2010. PLoS One 7: e44102.

101. Bertrand S,, Carion F,, Wintjens R,, Mathys V,, Vanhoof R. 2012. Evolutionary changes in antimicrobial resistance of invasive Neisseria meningitidis isolates in Belgium from 2000 to 2010: increasing prevalence of penicillin nonsusceptibility. Antimicrob Agents Chemother 56: 2268– 2272.

102. Hedberg ST,, Olcen P,, Fredlund H,, Unemo M. 2010. Antibiotic susceptibility of invasive Neisseria meningitidis isolates from 1995 to 2008 in Sweden—the meningococcal population remains susceptible. Scand J Infect Dis 42: 61– 64.

103. Brown EM,, Fisman DN,, Drews SJ,, Dolman S,, Rawte P,, Brown S,, Jamieson F. 2010. Epidemiology of invasive meningococcal disease with decreased susceptibility to penicillin in Ontario, Canada, 2000 to 2006. Antimicrob Agents Chemother 54: 1016– 1021.

104. du Plessis M,, Moodley C,, Mothibeli KM,, Fali A,, Klugman KP,, von Gottberg A. 2012. Population snapshot of invasive serogroup B meningococci in South Africa from 2005 to 2008. J Clin Microbiol 50: 2577– 2584.

105. Jorgensen JH,, Crawford SA,, Fiebelkorn KR. 2005. Susceptibility of Neisseria meningitidis to 16 antimicrobial agents and characterization of resistance mechanisms affecting some agents. J Clin Microbiol 43: 3162– 3171.

106. Richter SS,, Gordon KA,, Rhomberg PR,, Pfaller MA,, Jones RN. 2001. Neisseria meningitidis with decreased susceptibility to penicillin: report from the SENTRY antimicrobial surveillance program, North America, 1998–99. Diagn Microbiol Infect Dis 41: 83– 88.

107. Vazquez JA,, Enriquez R,, Abad R,, Alcala B,, Salcedo C,, Arreaza L. 2007. Antibiotic resistant meningococci in Europe: any need to act? FEMS Microbiol Rev 31: 64– 70.

108. Trotter CL,, Fox AJ,, Ramsay ME,, Sadler F,, Gray SJ,, Mallard R,, Kaczmarski EB. 2002. Fatal outcome from meningococcal disease——an association with meningococcal phenotype but not with reduced susceptibility to benzylpenicillin. J Med Microbiol 51: 855– 860.

109. Hansman D,, Wati S,, Lawrence A,, Turnidge J. 2004. Have South Australian isolates of Neisseria meningitidis become less susceptible to penicillin, rifampicin and other drugs? A study of strains isolated over three decades, 1971– 1999. Pathology 36: 160– 165.

110. Manchanda V,, Bhalla P. 2006. Emergence of non-ceftriaxone-susceptible Neisseria meningitidis in India. J Clin Microbiol 44: 4290– 4291.

111. Hedberg ST,, Fredlund H,, Nicolas P,, Caugant DA,, Olcen P,, Unemo M. 2009. Antibiotic susceptibility and characteristics of Neisseria meningitidis isolates from the African meningitis belt, 2000 to 2006: phenotypic and genotypic perspectives. Antimicrob Agents Chemother 53: 1561– 1566.

112. Taha MK,, Hedberg ST,, Szatanik M,, Hong E,, Ruckly C,, Abad R,, Bertrand S,, Carion F,, Claus H,, Corso A,, Enriquez R,, Heuberger S,, Hryniewicz W,, Jolley KA,, Kriz P,, Mollerach M,, Musilek M,, Neri A,, Olcen P,, Pana M,, Skoczynska A,, Sorhouet Pereira C,, Stefanelli P,, Tzanakaki G,, Unemo M,, Vazquez JA,, Vogel U,, Wasko I. 2010. Multicenter study for defining the breakpoint for rifampin resistance in Neisseria meningitidis by rpoB sequencing. Antimicrob Agents Chemother 54: 3651– 3658.

113. Mounchetrou Njoya I,, Deghmane A,, Taha M,, Isnard H,, Parent du Chatelet I. 2012. A cluster of meningococcal disease caused by rifampicin-resistant C meningococci in France, April 2012. Euro Surveill 17( 34): pii=20254.

114. Castanheira M,, Deshpande LM,, Jones RN,, Farrell DJ. 2012. Evaluation of quinolone resistance-determining region mutations and efflux pump expression in Neisseria meningitidis resistant to fluoroquinolones. Diagn Microbiol Infect Dis 72: 263– 266.

115. Wu HM,, Harcourt BH,, Hatcher CP,, Wei SC,, Novak RT,, Wang X,, Juni BA,, Glennen A,, Boxrud DJ,, Rainbow J,, Schmink S,, Mair RD,, Theodore MJ,, Sander MA,, Miller TK,, Kruger K,, Cohn AC,, Clark TA,, Messonnier NE,, Mayer LW,, Lynfield R. 2009. Emergence of ciprofloxacin-resistant Neisseria meningitidis in North America. N Engl J Med 360: 886– 892.

116. Rodriguez CN,, Rodriguez-Morales AJ,, Garcia A,, Pastran B,, Rios A,, Calvo A,, Jimenez I,, Meijomil P. 2005. Quinolone and azithromycin-resistant Neisseria meningitidis serogroup C causing urethritis in a heterosexual man. Int J STD AIDS 16: 649– 650.

117. Enriquez R,, Abad R,, Salcedo C,, Vazquez JA. 2009. Nalidixic acid disk for laboratory detection of ciprofloxacin resistance in Neisseria meningitidis. Antimicrob Agents Chemother 53: 796– 797.

118. Perez-Trallero E,, Gomez N,, Garcia-Arenzana JM. 1994. Etest as susceptibility test for evaluation of Neisseria meningitidis isolates. J Clin Microbiol 32: 2341– 2342.

119. Vazquez JA,, Arreaza L,, Block C,, Ehrhard I,, Gray SJ,, Heuberger S,, Hoffmann S,, Kriz P,, Nicolas P,, Olcen P,, Skoczynska A,, Spanjaard L,, Stefanelli P,, Taha MK,, Tzanakaki G. 2003. Interlaboratory comparison of agar dilution and Etest methods for determining the MICs of antibiotics used in management of Neisseria meningitidis infections. Antimicrob Agents Chemother 47: 3430– 3434.

120. Ross CL,, Thomason KS,, Koehler TM. 2009. An extracytoplasmic function sigma factor controls beta-lactamase gene expression in Bacillus anthracis and other Bacillus cereus group species. J Bacteriol 191: 6683– 6693.

121. Stern EJ,, Uhde KB,, Shadomy SV,, Messonnier N. 2008. Conference report on public health and clinical guidelines for anthrax. Emerg Infect Dis. 14( 4): e1.

122. Choe CH,, Bouhaouala SS,, Brook I,, Elliot TB,, Knudson GB. 2000. In vitro development of resistance to ofloxacin and doxycycline in Bacillus anthracis Sterne. Antimicrob Agents Chemother 44: 1766.

123. Price LB,, Vogler A,, Pearson T,, Busch JD,, Schupp JM,, Keim P. 2003. In vitro selection and characterization of Bacillus anthracis mutants with high-level resistance to ciprofloxacin. Antimicrob Agents Chemother 47: 2362– 2365.

124. Galimand M,, Guiyoule A,, Gerbaud G,, Rasoamanana B,, Chanteau S,, Carniel E,, Courvalin P. 1997. Multidrug resistance in Yersinia pestis mediated by a transferable plasmid. N Engl J Med 337: 677– 680.

125. Guiyoule A,, Gerbaud G,, Buchrieser C,, Galimand M,, Rahalison L,, Chanteau S,, Courvalin P,, Carniel E. 2001. Transferable plasmid-mediated resistance to streptomycin in a clinical isolate of Yersinia pestis. Emerg Infect Dis 7: 43– 48.

126. Urich SK,, Chalcraft L,, Schriefer ME,, Yockey BM,, Petersen JM. 2012. Lack of antimicrobial resistance in Yersinia pestis isolates from 17 countries in the Americas, Africa, and Asia. Antimicrob Agents Chemother 56: 555– 558.

127. Wagner D,, Runberg J,, Vogler AJ,, Lee J,, Driebe E,, Price L,, Engelthaler D,, Fricke W,, Ravel J,, Keim P. 2010. No resistance plasmid in Yersinia pestis, North America. Emerg Infect Dis 16: 885– 887.

128. Sarovich DS,, Price EP,, Von Schulze AT,, Cook JM,, Mayo M,, Watson LM,, Richardson L,, Seymour ML,, Tuanyok A,, Engelthaler DM,, Pearson T,, Peacock SJ,, Currie BJ,, Keim P,, Wagner DM. 2012. Characterization of ceftazidime resistance mechanisms in clinical isolates of Burkholderia pseudomallei from Australia. PLoS One 7: e30789.

129. Sam IC,, See KH,, Puthucheary SD. 2010. Susceptibility of Burkholderia pseudomallei to tigecycline and other antimicrobials. Diagn Microbiol Infect Dis 67: 308– 309.

130. Schweizer HP. 2012. Mechanisms of antibiotic resistance in Burkholderia pseudomallei: implications for treatment of melioidosis. Future Microbiol 7: 1389– 1399.

131. Thibault FM,, Hernandez E,, Vidal DR,, Girardet M,, Cavallo JD. 2004. Antibiotic susceptibility of 65 isolates of Burkholderia pseudomallei and Burkholderia mallei to 35 antimicrobial agents. J Antimicrob Chemother 54: 1134– 1138.

132. Sam IC,, See KH,, Puthucheary SD. 2009. Variations in ceftazidime and amoxicillin-clavulanate susceptibilities within a clonal infection of Burkholderia pseudomallei. J Clin Microbiol 47: 1556– 1558.

133. Baykam N,, Esener H,, Ergonul O,, Eren S,, Celikbas AK,, Dokuzoguz B. 2004. In vitro antimicrobial susceptibility of Brucella species. Int J Antimicrob Agents 23: 405– 407.

134. Kinsara A,, Al-Mowallad A,, Osoba AO. 1999. Increasing resistance of brucellae to co-trimoxazole. Antimicrob Agents Chemother 43: 1531.

135. Memish Z,, Mah MW,, Al Mahmoud S,, Al Shaalan M,, Khan MY. 2000. Brucella bacteraemia: clinical and laboratory observations in 160 patients. J Infect 40: 59– 63.

136. Sayan M,, Kilic S,, Uyanik MH. 2012. Epidemiological survey of rifampicin resistance in clinic isolates of Brucella melitensis obtained from all regions of Turkey. J Infect Chemother 18: 41– 46.

137. Marianelli C,, Ciuchini F,, Tarantino M,, Pasquali P,, Adone R. 2004. Genetic bases of the rifampin resistance phenotype in Brucella spp. J Clin Microbiol 42: 5439– 5443.

138. Valdezate S,, Navarro A,, Medina-Pascual MJ,, Carrasco G,, Saez-Nieto JA. 2010. Molecular screening for rifampicin and fluoroquinolone resistance in a clinical population of Brucella melitensis. J Antimicrob Chemother 65: 51– 53.

139. Antunes NT,, Frase H,, Toth M,, Vakulenko SB. 2012. The class A beta-lactamase FTU-1 is native to Francisella tularensis. Antimicrob Agents Chemother 56: 666– 671.

140. Baker CN,, Hollis DG,, Thornsberry C. 1985. Antimicrobial susceptibility testing of Francisella tularensis with a modified Mueller-Hinton broth. J Clin Microbiol 22: 212– 215.

141. Ikaheimo I,, Syrjala H,, Karhukorpi J,, Schildt R,, Koskela M. 2000. In vitro antibiotic susceptibility of Francisella tularensis isolated from humans and animals. J Antimicrob Chemother 46: 287– 290.

142. Yesilyurt M,, Kilic S,, Celebi B,, Celik M,, Gul S,, Erdogan F,, Ozel G. 2011. Antimicrobial susceptibilities of Francisella tularensis subsp. holarctica strains isolated from humans in the Central Anatolia region of Turkey. J Antimicrob Chemother 66: 2588– 2592.

143. Lonsway DR,, Jevitt LA,, Uhl JR,, Cockerill FR III,, Anderson ME,, Sullivan MM,, De BK,, Edwards JR,, Patel JB. 2010. Effect of carbon dioxide on broth microdilution susceptibility testing of Brucella spp. J Clin Microbiol 48: 952– 956.

144. Mohammed MJ,, Marston CK,, Popovic T,, Weyant RS,, Tenover FC. 2002. Antimicrobial susceptibility testing of Bacillus anthracis: comparison of results obtained by using the National Committee for Clinical Laboratory Standards broth microdilution reference and Etest agar gradient diffusion methods. J Clin Microbiol 40: 1902– 1907.

145. Turnbull PCB,, Sirianni NM,, LeBron CI,, Samaan MN,, Sutton FN,, Reyes AE,, Peruski LF Jr. 2004. MICs of selected antibiotics for Bacillus anthracis, Bacillus cereus, Bacillus thuringiensis, and Bacillus mycoides from a range of clinical and environmental sources as determined by the Etest. J Clin Microbiol 42: 3626– 3634.

146. Lonsway DR,, Urich SK,, Heine HS,, McAllister SK,, Banerjee SN,, Schriefer ME,, Patel JB. 2011. Comparison of Etest method with reference broth microdilution method for antimicrobial susceptibility testing of Yersinia pestis. J Clin Microbiol 49: 1956– 1960.

147. Weigel LM,, Sue D,, Michel PA,, Kitchel B,, Pillai SP. 2010. A rapid antimicrobial susceptibility test for Bacillus anthracis. Antimicrob Agents Chemother 54: 2793– 2800.

148. Loveless BM,, Yermakova A,, Christensen DR,, Kondig JP,, Heine HS III,, Wasieloski LP,, Kulesh DA. 2010. Identification of ciprofloxacin resistance by SimpleProbe, high resolution melt and pyrosequencing nucleic acid analysis in biothreat agents: Bacillus anthracis, Yersinia pestis and Francisella tularensis. Mol Cell Probes 24: 154– 160.

149. Song J,, Li PE,, Gans J,, Vuyisich M,, Deshpande A,, Wolinsky M,, White PS. 2010. Simultaneous pathogen detection and antibiotic resistance characterization using SNP-based multiplexed oligonucleotide ligation-PCR (MOL-PCR). Adv Exp Med Biol 680: 455– 464.

150. Wilson DE,, Chosewood LC ( ed). 2009. Biosafety in Microbiological and Biomedical Laboratories, 5th ed. US Government Printing Office, Washington, DC.

151. Murray CK,, Walter EA,, Crawford S,, McElmeel ML,, Jorgensen JH. 2001. Abiotrophia bacteremia in a patient with neutropenic fever and antimicrobial susceptibility testing of Abiotrophia isolates. Clin Infect Dis 32: E140– E142.

152. Liao CH,, Teng LJ,, Hsueh PR,, Chen YC,, Huang LM,, Chang SC,, Ho SW. 2004. Nutritionally variant streptococcal infections at a University Hospital in Taiwan: disease emergence and high prevalence of beta-lactam and macrolide resistance. Clin Infect Dis 38: 452– 455.

153. Tuohy M,, Procop G,, Washington J. 2000. Antimicrobial susceptibility of Abiotrophia adiacens and Abiotrophia defectiva. Diagn Microbiol Infect Dis 38: 189– 191.

154. Poyart C,, Quesne G,, Acar P,, Berche P,, Trieu-Cuot P. 2000. Characterization of the Tn916-like transposon Tn3872 in a strain of Abiotrophia defectiva ( Streptococcus defectivus) causing sequential episodes of endocarditis in a child. Antimicrob Agents Chemother 44: 790– 793.

155. Zheng X,, Freeman AF,, Villafranca J,, Shortridge D,, Beyer J,, Kabat W,, Dembkowski K,, Shulman ST. 2004. Antimicrobial susceptibilities of invasive pediatric Abiotrophia and Granulicatella isolates. J Clin Microbiol 42: 4323– 4326.

156. Namdari H,, Kintner K,, Jackson BA,, Namdari S,, Hughes JL,, Peairs RR,, Savage DJ. 1999. Abiotrophia species as a cause of endophthalmitis following cataract extraction. J Clin Microbiol 37: 1564– 1566.

157. Lamy B,, Kodjo A,, Laurent F. 2009. Prospective nationwide study of Aeromonas infections in France. J Clin Microbiol 47: 1234– 1237.

158. Ko W,, Yu K,, Liu C,, Huang C,, Leu H,, Chuang Y. 1996. Increasing antibiotic resistance in clinical isolates of Aeromonas strains in Taiwan. Antimicrob Agents Chemother 40: 1260– 1262.

159. Vila J,, Marco F,, Soler L,, Chacon M,, Figueras MJ. 2002. In vitro antimicrobial susceptibility of clinical isolates of Aeromonas caviae, Aeromonas hydrophila and Aeromonas veronii biotype sobria. J Antimicrob Chemother 49: 701– 702.

160. Janda JM,, Abbott SL. 2010. The genus Aeromonas: taxonomy, pathogenicity, and infection. Clin Microbiol Rev 23: 35– 73.

161. Ko W-C,, Wu H-M,, Chang T-C,, Yan J-J,, Wu J-J. 1998. Inducible beta-lactam resistance in Aeromonas hydrophila: therapeutic challenge for antimicrobial therapy. J Clin Microbiol 36: 3188– 3192.

162. Castanheira M,, Jones RN,, Livermore DM. 2009. Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp. Diagn Microbiol Infect Dis 63: 426– 433.

163. Liu YM,, Chen YS,, Toh HS,, Huang CC,, Lee YL,, Ho CM,, Lu PL,, Ko WC,, Chen YH,, Wang JH,, Tang HJ,, Yu KW,, Liu YC,, Chuang YC,, Xu Y,, Ni Y,, Liu CE,, Hsueh PR. 2012. In vitro susceptibilities of non- Enterobacteriaceae isolates from patients with intra-abdominal infections in the Asia-Pacific region from 2003 to 2010: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). Int J Antimicrob Agents 40( Suppl) : S11– S17.

164. Libisch B,, Giske CG,, Kovacs B,, Toth TG,, Fuzi M. 2008. Identification of the first VIM metallo-beta-lactamase-producing multiresistant Aeromonas hydrophila strain. J Clin Microbiol 46: 1878– 1880.

165. Neuwirth C,, Siebor E,, Robin F,, Bonnet R. 2007. First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France. Antimicrob Agents Chemother 51: 4486– 4488.

166. Arias A,, Seral C,, Gude MJ,, Castillo FJ. 2010. Molecular mechanisms of quinolone resistance in clinical isolates of Aeromonas caviae and Aeromonas veronii bv. sobria. Int Microbiol 13: 135– 141.

167. Sinha S,, Chattopadhyay S,, Bhattacharya SK,, Nair GB,, Ramamurthy T. 2004. An unusually high level of quinolone resistance associated with type II topoisomerase mutations in quinolone resistance-determining regions of Aeromonas caviae isolated from diarrhoeal patients. Res Microbiol 155: 827– 829.

168. Giltner CL,, Bobenchik AM,, Uslan DZ,, Deville JG,, Humphries RM. 2013. Ciprofloxacin-resistant Aeromonas hydrophila cellulitis following leech therapy. J Clin Microbiol 51: 1324– 1326.

169. Patel KM,, Svestka M,, Sinkin J,, Ruff PT. 2013. Ciprofloxacin-resistant Aeromonas hydrophila infection following leech therapy: a case report and review of the literature. J Plast Reconstr Aesthet Surg 66: e20– e22.

170. Gonzalez-Rey C,, Svenson SB,, Bravo L,, Siitonen A,, Pasquale V,, Dumontet S,, Ciznar I,, Krovacek K. 2004. Serotypes and anti-microbial susceptibility of Plesiomonas shigelloides isolates from humans, animals and aquatic environments in different countries. Comp Immunol Microbiol Infect Dis 27: 129– 139.

171. Stock I,, Wiedemann B. 2001. Natural antimicrobial susceptibilities of Plesiomonas shigelloides strains. J Antimicrob Chemother 48: 803– 811.

172. Weber DJ,, Saviteer SM,, Rutala WA,, Thomann CA. 1988. In vitro susceptibility of Bacillus spp. to selected antimicrobial agents. Antimicrob Agents Chemother 32: 642– 645.

173. Citron DM,, Appleman MD. 2006. In vitro activities of daptomycin, ciprofloxacin, and other antimicrobial agents against the cells and spores of clinical isolates of Bacillus species. J Clin Microbiol 44: 3814– 3818.

174. Kiyomizu K,, Yagi T,, Yoshida H,, Minami R,, Tanimura A,, Karasuno T,, Hiraoka A. 2008. Fulminant septicemia of Bacillus cereus resistant to carbapenem in a patient with biphenotypic acute leukemia. J Infect Chemother 14: 361– 367.

175. Andrews JM,, Wise R. 2002. Susceptibility testing of Bacillus species. J Antimicrob Chemother 49: 1040– 1042.

176. Centers for Disease Control and Prevention. 2013. National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS): Human Isolates Final Report, 2011. US Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA.

177. Engberg J,, Aarestrup FM,, Taylor DE,, Gerner-Smidt P,, Nachamkin I. 2001. Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: resistance mechanisms and trends in human isolates. Emerg Infect Dis 7: 24– 34.

178. Griggs DJ,, Johnson MM,, Frost JA,, Humphrey T,, Jorgensen F,, Piddock LJ. 2005. Incidence and mechanism of ciprofloxacin resistance in Campylobacter spp. isolated from commercial poultry flocks in the United Kingdom before, during, and after fluoroquinolone treatment. Antimicrob Agents Chemother 49: 699– 707.

179. Luo N,, Pereira S,, Sahin O,, Lin J,, Huang S,, Michel L,, Zhang Q. 2005. Enhanced in vivo fitness of fluoroquinolone-resistant Campylobacter jejuni in the absence of antibiotic selection pressure. Proc Natl Acad Sci U S A 102: 541– 546.

180. Bakeli G,, Sato K,, Kumita W,, Saito R,, Ono E,, Chida T,, Okamura N. 2008. Antimicrobial susceptibility and mechanism of quinolone resistance in Campylobacter jejuni strains isolated from diarrheal patients in a hospital in Tokyo. J Infect Chemother 14: 342– 348.

181. Wassenaar TM,, Kist M,, de Jong A. 2007. Re-analysis of the risks attributed to ciprofloxacin-resistant Campylobacter jejuni infections. Int J Antimicrob Agents 30: 195– 201.

182. Gaudreau C,, Girouard Y,, Ringuette L,, Tsimiklis C. 2007. Comparison of disk diffusion and agar dilution methods for erythromycin and ciprofloxacin susceptibility testing of Campylobacter jejuni subsp . jejuni. Antimicrob Agents Chemother 51: 1524– 1526.

183. Gaudreau C,, Girouard Y,, Gilbert H,, Gagnon J,, Bekal S. 2008. Comparison of disk diffusion and agar dilution methods for erythromycin, ciprofloxacin, and tetracycline susceptibility testing of Campylobacter coli and for tetracycline susceptibility testing of Campylobacter jejuni subsp. jejuni. Antimicrob Agents Chemother 52: 4475– 4477.

184. Baker CN. 1992. The E-Test and Campylobacter jejuni. Diagn Microbiol Infect Dis 15: 469– 472.

185. Fernandez-Roblas R,, Adames H,, Martin-de-Hijas NZ,, Almeida DG,, Gadea I,, Esteban J. 2009. In vitro activity of tigecycline and 10 other antimicrobials against clinical isolates of the genus Corynebacterium. Int J Antimicrob Agents 33: 453– 435.

186. Funke G,, Punter V,, von Graevenitz A. 1996. Antimicrobial susceptibility patterns of some recently established coryneform bacteria. Antimicrob Agents Chemother 40: 2874– 2878.

187. Gomez-Garces JL,, Alos JI,, Tamayo J. 2007. In vitro activity of linezolid and 12 other antimicrobials against coryneform bacteria. Int J Antimicrob Agents 29: 688– 692.

188. Weiss K,, Laverdiere M,, Rivest R. 1996. Comparison of antimicrobial susceptibility of Corynebacterium species by broth microdilution and disk diffusion. Antimicrob Agents Chemother 40: 930– 933.

189. Bernard K. 2012. The genus Corynebacterium and other medically relevant coryneform-like bacteria. J Clin Microbiol 50: 3152– 3158.

190. Tran TT,, Jaijakul S,, Lewis CT,, Diaz L,, Panesso D,, Kaplan HB,, Murray BE,, Wanger A,, Arias CA. 2012. Native valve endocarditis caused by Corynebacterium striatum with heterogeneous high-level daptomycin resistance: collateral damage from daptomycin therapy? Antimicrob Agents Chemother 56: 3461– 3464.

191. Soriano F,, Tauch A. 2008. Microbiological and clinical features of Corynebacterium urealyticum: urinary tract stones and genomics as the Rosetta Stone. Clin Microbiol Infect 14: 632– 643.

192. Eguchi H,, Kuwahara T,, Miyamoto T,, Nakayama-Imaohji H,, Ichimura M,, Hayashi T,, Shiota H. 2008. High-level fluoroquinolone resistance in ophthalmic clinical isolates belonging to the species Corynebacterium macginleyi. J Clin Microbiol 46: 527– 532.

193. Ortiz-Perez A,, Martin-de-Hijas NZ,, Esteban J,, Fernandez-Natal MI,, Garcia-Cia JI,, Fernandez-Roblas R. 2010. High frequency of macrolide resistance mechanisms in clinical isolates of Corynebacterium species. Microb Drug Resist 16: 273– 277.

194. Engler KH,, Warner M,, George RC. 2001. In vitro activity of ketolides HMR 3004 and HMR 3647 and seven other antimicrobial agents against Corynebacterium diphtheriae. J Antimicrob Chemother 47: 27– 31.

195. Pereira GA,, Pimenta FP,, Santos FR,, Damasco PV,, Hirata R Jr,, Mattos-Guaraldi AL. 2008. Antimicrobial resistance among Brazilian Corynebacterium diphtheriae strains. Mem Inst Oswaldo Cruz 103: 507– 510.

196. Mina NV,, Burdz T,, Wiebe D,, Rai JS,, Rahim T,, Shing F,, Hoang L,, Bernard K. 2011. Canada’s first case of a multidrug-resistant Corynebacterium diphtheriae strain, isolated from a skin abscess. J Clin Microbiol 49: 4003– 4005.

197. von Hunolstein C,, Scopetti F,, Efstratiou A,, Engler K. 2002. Penicillin tolerance amongst non-toxigenic Corynebacterium diphtheriae isolated from cases of pharyngitis. J Antimicrob Chemother 50: 125– 128.

198. Grandiere-Perez L,, Jacqueline C,, Lemabecque V,, Patey O,, Potel G,, Caillon J. 2005. Eagle effect in Corynebacterium diphtheriae. J Infect Dis 191: 2118– 2120.

199. Barraud O,, Badell E,, Denis F,, Guiso N,, Ploy MC. 2011. Antimicrobial drug resistance in Corynebacterium diphtheriae mitis. Emerg Infect Dis 17: 2078– 2080.

200. Garcia-de-la-Fuente C,, Ruiz De Alegria C,, Cano ME,, Campo AB,, Unda F,, Aguero J,, Martinez-Martinez L. 2012. Phenotypic and molecular characterization of Arcanobacterium haemolyticum isolated from clinical samples. Diagn Microbiol Infect Dis 72: 1– 7.

201. Power EG,, Abdulla YH,, Talsania HG,, Spice W,, Aathithan S,, French GL. 1995. vanA genes in vancomycin-resistant clinical isolates of Oerskovia turbata and Arcanobacterium ( Corynebacterium) haemolyticum. J Antimicrob Chemother 36: 595– 606.

202. Funke G,, Lawson PA,, Nolte FS,, Weiss N,, Collins MD. 1998. Aureobacterium resistens sp. nov., exhibiting vancomycin resistance and teicoplanin susceptibility. FEMS Microbiol Lett 158: 89– 93.

203. Boumghar-Bourtchai L,, Chardon H,, Malbruny B,, Mezghani S,, Leclercq R,, Dhalluin A. 2009. Resistance to macrolides by ribosomal mutation in clinical isolates of Turicella otitidis. Int J Antimicrob Agents 34: 274– 277.

204. Gomez-Garces JL,, Alhambra A,, Alos JI,, Barrera B,, Garcia G. 2004. Acute and chronic otitis media and Turicella otitidis: a controversial association. Clin Microbiol Infect 10: 854– 857.

205. Fidalgo SG,, Longbottom CJ,, Rjley TV. 2002. Susceptibility of Erysipelothrix rhusiopathiae to antimicrobial agents and home disinfectants. Pathology 34: 462– 465.

206. Ozawa M,, Yamamoto K,, Kojima A,, Takagi M,, Takahashi T. 2009. Etiological and biological characteristics of Erysipelothrix rhusiopathiae isolated between 1994 and 2001 from pigs with swine erysipelas in Japan. J Vet Med Sci 71: 697– 702.

207. Yamamoto K,, Kijima M,, Yoshimura H,, Takahashi T. 2001. Antimicrobial susceptibilities of Erysipelothrix rhusiopathiae isolated from pigs with swine erysipelas in Japan, 1988–1998. J Vet Med Ser B 48: 115– 126.

208. Yamamoto K,, Sasaki Y,, Ogikubo Y,, Noguchi N,, Sasatsu M,, and Takahashi T. 2001. Identification of the tetracycline resistance gene, tet(M), in Erysipelothrix rhusiopathiae. J Vet Med Ser B 48: 293– 301.

209. Piper KE,, Steckelberg JM,, Patel R. 2005. In vitro activity of daptomycin against clinical isolates of gram-positive bacteria. J Infect Chemother 11: 207– 209.

210. Kugler KC,, Biedenbach DJ,, Jones RN. 1999. Determination of the antimicrobial activity of 29 clinically important compounds tested against fastidious HACEK group organisms. Diagn Microbiol Infect Dis 34: 73– 76.

211. Coburn B,, Toye B,, Rawte P,, Jamieson FB,, Farrell DJ,, Patel SN. 2013. Antimicrobial susceptibilities of clinical isolates of HACEK organisms. Antimicrob Agents Chemother 57: 1989– 1991.

212. Wueppenhorst N,, Stueger HP,, Kist M,, Glocker EO. 2013. High secondary resistance to quinolones in German Helicobacter pylori clinical isolates. J Antimicrob Chemother 68: 1562– 1566.

213. McNulty CA,, Lasseter G,, Shaw I,, Nichols T,, D’Arcy S,, Lawson AJ,, Glocker E. 2012. Is Helicobacter pylori antibiotic resistance surveillance needed and how can it be delivered? Aliment Pharmacol Ther 35: 1221– 1230.

214. Tveit AH,, Bruce MG,, Bruden DL,, Morris J,, Reasonover A,, Hurlburt DA,, Hennessy TW,, McMahon B. 2011. Alaska sentinel surveillance study of Helicobacter pylori isolates from Alaska Native persons from 2000 to 2008. J Clin Microbiol 49: 3638– 3643.

215. Duck WM,, Sobel J,, Pruckler JM,, Song Q,, Swerdlow D,, Friedman C,, Sulka A,, Swaminathan B,, Taylor T,, Hoekstra M,, Griffin P,, Smoot D,, Peek R,, Metz DC,, Bloom PB,, Goldschmidt S,, Parsonnet J,, Triadafilopoulos G,, Perez-Perez GI,, Vakil N,, Ernst P,, Czinn S,, Dunne D,, Gold BD. 2004. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis 10: 1088– 1094.

216. Kobayashi I,, Murakami K,, Kato M,, Kato S,, Azuma T,, Takahashi S,, Uemura N,, Katsuyama T,, Fukuda Y,, Haruma K,, Nasu M,, Fujioka T. 2007. Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J Clin Microbiol 45: 4006– 4010.

217. Glupczynski Y,, Broutet N,, Cantagrel A,, Andersen LP,, Alarcon T,, Lopez-Brea M,, Megraud F. 2002. Comparison of the E test and agar dilution method for antimicrobial suceptibility testing of Helicobacter pylori. Eur J Clin Microbiol Infect Dis 21: 549– 552.

218. Grignon B,, Tankovic J,, Megraud F,, Glupczynski Y,, Husson MO,, Conroy MC,, Emond JP,, Loulergue J,, Raymond J,, Fauchere JL. 2002. Validation of diffusion methods for macrolide susceptibility testing of Helicobacter pylori. Microb Drug Resist 8: 61– 66.

219. Owen RJ. 2002. Molecular testing for antibiotic resistance in Helicobacter pylori. Gut 50: 285– 289.

220. Piccolomini R,, Di Bonaventura G,, Catamo G,, Carbone F,, Neri M. 1997. Comparative evaluation of the E test, agar dilution, and broth microdilution for testing susceptibilities of Helicobacter pylori strains to 20 antimicrobial agents. J Clin Microbiol 35: 1842– 1846.

221. Best LM,, Haldane DJ,, Keelan M,, Taylor DE,, Thomson AB,, Loo V,, Fallone CA,, Lyn P,, Smaill FM,, Hunt R,, Gaudreau C,, Kennedy J,, Alfa M,, Pelletier R,, Veldhuyzen Van Zanten SJ. 2003. Multilaboratory comparison of proficiencies in susceptibility testing of Helicobacter pylori and correlation between agar dilution and E test methods. Antimicrob Agents Chemother 47: 3138– 3144.

222. Osato MS,, Reddy R,, Reddy SG,, Penland RL,, Graham DY. 2001. Comparison of the Etest and the NCCLS-approved agar dilution method to detect metronidazole and clarithromycin resistant Helicobacter pylori. Int J Antimicrob Agents 17: 39– 44.

223. Chida-Sakata N,, Baba M,, Inagawa H,, Wada A,, Tanaka T,, Hoshihara Y,, Takemoto T. 1999. Significance of anaerobic preincubation of Helicobacter pylori for measuring metronidazole susceptibility by the Etest. Microbiol Immunol 43: 397– 401.

224. De Francesco V,, Zullo A,, Ierardi E,, Giorgio F,, Perna F,, Hassan C,, Morini S,, Panella C,, Vaira D. 2010. Phenotypic and genotypic Helicobacter pylori clarithromycin resistance and therapeutic outcome: benefits and limits. J Antimicrob Chemother 65: 327– 332.

225. Kim JJ,, Kim JG,, Kwon DH. 2003. Mixed-infection of antibiotic susceptible and resistant Helicobacter pylori isolates in a single patient and underestimation of antimicrobial susceptibility testing. Helicobacter 8: 202– 206.

226. Cannon JP,, Lee TA,, Bolanos JT,, Danziger LH. 2005. Pathogenic relevance of Lactobacillus: a retrospective review of over 200 cases. Eur J Clin Microbiol Infect Dis 24: 31– 40.

227. Delgado S,, Florez AB,, Mayo B. 2005. Antibiotic susceptibility of Lactobacillus and Bifidobacterium species from the human gastrointestinal tract. Curr Microbiol 50: 202– 207.

228. Klare I,, Konstabel C,, Werner G,, Huys G,, Vankerckhoven V,, Kahlmeter G,, Hildebrandt B,, Muller-Bertling S,, Witte W,, Goossens H. 2007. Antimicrobial susceptibilities of Lactobacillus, Pediococcus and Lactococcus human isolates and cultures intended for probiotic or nutritional use. J Antimicrob Chemother 59: 900– 912.

229. Salminen MK,, Rautelin H,, Tynkkynen S,, Poussa T,, Saxelin M,, Valtonen V,, Jarvinen A. 2006. Lactobacillus bacteremia, species identification, and antimicrobial susceptibility of 85 blood isolates. Clin Infect Dis 42: e35– e44.

230. Vay C,, Cittadini R,, Barberis C,, Hernan Rodriguez C,, Perez Martinez H,, Genero F,, Famiglietti A. 2007. Antimicrobial susceptibility of non-enterococcal intrinsic glycopeptide-resistant gram-positive organisms. Diagn Microbiol Infect Dis 57: 183– 188.

231. Swenson JM,, Facklam RR,, Thornsberry C. 1990. Antimicrobial susceptibility of vancomycin-resistant Leuconostoc, Pediococcus, and Lactobacillus species. Antimicrob Agents Chemother 34: 543– 549.

232. Svec P,, Sevcikova A,, Sedlacek I,, Bednarova J,, Snauwaert C,, Lefebvre K,, Vandamme P,, Vancanneyt M. 2007. Identification of lactic acid bacteria isolated from human blood cultures. FEMS Immunol Med Microbiol 49: 192– 196.

233. Lee MR,, Huang YT,, Lee PI,, Liao CH,, Lai CC,, Lee LN,, Hsueh PR. 2011. Healthcare-associated bacteraemia caused by Leuconostoc species at a university hospital in Taiwan between 1995 and 2008. J Hosp Infect 78: 45– 49.

234. Deye G,, Lewis J,, Patterson J,, Jorgensen J. 2003. A case of Leuconostoc ventriculitis with resistance to carbapenem antibiotics. Clin Infect Dis 37: 869– 870.

235. Rolston KV,, Kapadia M,, Tarrand J,, Coyle E,, Prince RA. 2013. Spectrum of gram-positive bacteraemia and in vitro activities of daptomycin, linezolid and vancomycin against organisms isolated from cancer patients. Int J Antimicrob Agents 41: 516– 520.

236. Danielsen M,, Simpson PJ,, O’Connor EB,, Ross RP,, Stanton C. 2007. Susceptibility of Pediococcus spp. to antimicrobial agents. J Appl Microbiol 102: 384– 389.

237. Morvan A,, Moubareck C,, Leclercq A,, Herve-Bazin M,, Bremont S,, Lecuit M,, Courvalin P,, Le Monnier A. 2010. Antimicrobial resistance of Listeria monocytogenes strains isolated from humans in France. Antimicrob Agents Chemother 54: 2728– 2731.

238. Huang YT,, Liao CH,, Teng LJ,, Hsueh PR. 2007. Daptomycin susceptibility of unusual gram-positive bacteria: comparison of results obtained by the Etest and the broth microdilution method. Antimicrob Agents Chemother 51: 1570– 1572.

239. Lungu B,, O’Bryan CA,, Muthaiyan A,, Milillo SR,, Johnson MG,, Crandall PG,, Ricke SC. 2011. Listeria monocytogenes: antibiotic resistance in food production. Foodborne Pathog Dis 8: 569– 578.

240. Rakic-Martinez M,, Drevets DA,, Dutta V,, Katic V,, Kathariou S. 2011. Listeria monocytogenes strains selected on ciprofloxacin or the disinfectant benzalkonium chloride exhibit reduced susceptibility to ciprofloxacin, gentamicin, benzalkonium chloride, and other toxic compounds. Appl Environ Microbiol 77: 8714– 8721.

241. Davis JA,, Jackson CR. 2009. Comparative antimicrobial susceptibility of Listeria monocytogenes, L. innocua, and L. welshimeri. Microb Drug Resist 15: 27– 32.

242. Hsu SF,, Lin YT,, Chen TL,, Siu LK,, Hsueh PR,, Huang ST,, Fung CP. 2012. Antimicrobial resistance of Moraxella catarrhalis isolates in Taiwan. J Microbiol Immunol Infect 45: 134– 140.

243. Khan MA,, Northwood JB,, Levy F,, Verhaegh SJ,, Farrell DJ,, Van Belkum A,, Hays JP. 2010. bro β-lactamase and antibiotic resistances in a global cross-sectional study of Moraxella catarrhalis from children and adults. J Antimicrob Chemother 65: 91– 97.

244. Bell JM,, Turnidge JD,, Jones RN. 2009. Development of a disk diffusion method for testing Moraxella catarrhalis susceptibility using clinical and laboratory standards institute methods: a SENTRY antimicrobial surveillance program report. J Clin Microbiol 47: 2187– 2193.

245. Deshpande LM,, Sader HS,, Fritsche TR,, Jones RN. 2006. Contemporary prevalence of BRO beta-lactamases in Moraxella catarrhalis: report from the SENTRY antimicrobial surveillance program (North America, 1997 to 2004). J Clin Microbiol 44: 3775– 3777.

246. Esel D,, Ay-Altintop Y,, Yagmur G,, Gokahmetoglu S,, Sumerkan B. 2007. Evaluation of susceptibility patterns and BRO beta-lactamase types among clinical isolates of Moraxella catarrhalis. Clin Microbiol Infect 13: 1023– 1025.

247. Kadry AA,, Fouda SI,, Elkhizzi NA,, Shibl AM. 2003. Correlation between susceptibility and BRO type enzyme of Moraxella catarrhalis strains. Int J Antimicrob Agents 22: 532– 536.

248. Flamm RK,, Sader HS,, Farrell DJ,, Jones RN. 2012. Macrolide and tetracycline resistance among Moraxella catarrhalis isolates from 2009 to 2011. Diagn Microbiol Infect Dis 74: 198– 200.

249. Citron DM,, Warren YA,, Fernandez HT,, Goldstein MA,, Tyrrell KL,, Goldstein EJ. 2005. Broth microdilution and disk diffusion tests for susceptibility testing of Pasteurella species isolated from human clinical specimens. J Clin Microbiol 43: 2485– 2488.

250. Goldstein EJ,, Citron DM,, Merriam CV,, Warren YA,, Tyrrell KL,, Fernandez HT. 2002. In vitro activities of garenoxacin (BMS-284756) against 170 clinical isolates of nine Pasteurella species. Antimicrob Agents Chemother 46: 3068– 3070.

251. Lion C,, Conroy MC,, Carpentier AM,, Lozniewski A. 2006. Antimicrobial susceptibilities of Pasteurella strains isolated from humans. Int J Antimicrob Agents 27: 290– 293.

252. Mortensen JE,, Giger O,, Rodgers GL. 1998. In vitro activity of oral antimicrobial agents against clinical isolates of Pasteurella multocida. Diagn Microbiol Infect Dis 30: 99– 102.

253. Lion C,, Lozniewski A,, Rosner V,, Weber M. 1999. Lung abscess due to beta-lactamase-producing Pasteurella multocida. Clin Infect Dis 29: 1345– 1346.

254. Naas T,, Benaoudia F,, Lebrun L,, Nordmann P. 2001. Molecular identification of TEM-1 beta-lactamase in a Pasteurella multocida isolate of human origin. Eur J Clin Microbiol Infect Dis 20: 210– 213.

255. Goldstein EJ,, Citron DM,, Merriam CV,, Tyrrell KL. 2012. Ceftaroline versus isolates from animal bite wounds: comparative in vitro activities against 243 isolates, including 156 Pasteurella species isolates. Antimicrob Agents Chemother 56: 6319– 6323.

256. Levin JM,, Talan DA. 1990. Erythromycin failure with subsequent Pasteurella multocida meningitis and septic arthritis in a cat-bite victim. Ann Emerg Med 19: 1458– 1461.

257. Okeke IN,, Aboderin OA,, Byarugaba DK,, Ojo KK,, Opintan JA. 2007. Growing problem of multidrug-resistant enteric pathogens in Africa. Emerg Infect Dis 13: 1640– 1646.

258. Kitaoka M,,, Miyata ST,,, Unterweger D,, Pukatzki S. 2011. Antibiotic resistance mechanisms of Vibrio cholerae. J Med Microbiol 60: 397– 407.

259. Pan JC,, Ye R,, Wang HQ,, Xiang HQ,, Zhang W,, Yu XF,, Meng DM,, He ZS. 2008. Vibrio cholerae O139 multiple-drug resistance mediated by Yersinia pestis pIP1202-like conjugative plasmids. Antimicrob Agents Chemother 52: 3829– 3836.

260. Igbinosa EO,, Okoh AI. 2008. Emerging Vibrio species: an unending threat to public health in developing countries. Res Microbiol 159: 495– 506.

261. Wang R,, Lou J,, Liu J,, Zhang L,, Li J,, Kan B. 2012. Antibiotic resistance of Vibrio cholerae O1 El Tor strains from the seventh pandemic in China, 1961–2010. Int J Antimicrob Agents 40: 361– 364.

262. Yu L,, Zhou Y,, Wang R,, Lou J,, Zhang L,, Li J,, Bi Z,, Kan B. 2012. Multiple antibiotic resistance of Vibrio cholerae serogroup O139 in China from 1993 to 2009. PLoS One 7: e38633.

263. Mandal J,, Sangeetha V,, Ganesan V,, Parveen M,, Preethi V,, Harish BN,, Srinivasan S,, Parija SC. 2012. Third-generation cephalosporin-resistant V ibrio cholerae, India. Emerg Infect Dis 18: 1326– 1328.

264. Saha D,, Karim MM,, Khan WA,, Ahmed S,, Salam MA,, Bennish ML. 2006. Single-dose azithromycin for the treatment of cholera in adults. N Engl J Med 354: 2452– 2462.

Tables

Susceptibility Test Methods: Fastidious Bacteria*

[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555817381.mcm11.ch74-1,webId=/content/author/10.1128/9781555817381.mcm11.ch74-1,properties={foaf_givenname=Romney M., foaf_name=Romney M. Humphries, foaf_surname=Humphries}], com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555817381.mcm11.ch74-2,webId=/content/author/10.1128/9781555817381.mcm11.ch74-2,properties={foaf_givenname=Janet A., foaf_name=Janet A. Hindler, foaf_surname=Hindler}]]

/content/10.1128/9781555817381.mcm11.ch74.ch74.tab001

TABLE 1

Disk diffusion and MIC testing conditions and recommended QC strains for selected fastidious bacteria

TABLE 1

Disk diffusion and MIC testing conditions and recommended QC strains for selected fastidious bacteria

/content/10.1128/9781555817381.mcm11.ch74.ch74.tab002

TABLE 2

Broth microdilution MIC testing conditions, recommended QC strains, and drugs recommended for testing potential agents of bioterrorism

TABLE 2

Broth microdilution MIC testing conditions, recommended QC strains, and drugs recommended for testing potential agents of bioterrorism

/content/10.1128/9781555817381.mcm11.ch74.ch74.tab003

TABLE 3

Disk diffusion and MIC testing conditions, recommended QC strains, and agents to consider for primary testing for infrequently isolated or less common fastidious bacteria

TABLE 3

Disk diffusion and MIC testing conditions, recommended QC strains, and agents to consider for primary testing for infrequently isolated or less common fastidious bacteria